Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series
Eur Respir J
.
2020 Jan 23;55(1):1901333.
doi: 10.1183/13993003.01333-2019.
Print 2020 Jan.
Authors
Jessica Rademacher
1
2
,
Stefanie Konwert
3
,
Jan Fuge
2
,
Sabine Dettmer
2
4
,
Tobias Welte
3
2
,
Felix C Ringshausen
3
2
Affiliations
1
Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany rademacher.jessica@mh-hannover.de.
2
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
3
Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
4
Dept of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
PMID:
31619477
DOI:
10.1183/13993003.01333-2019
No abstract available
Publication types
Letter
MeSH terms
Bronchiectasis* / drug therapy
Humans